ROCKVILLE, MD and SHENZHEN, CHINA, October 15, 2024—HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, ann

ROCKVILLE, MD and SHENZHEN, CHINA, September 30, 2024—HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, a

ROCKVILLE, MD and SHENZHEN, CHINA, September 19, 2024—HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, a

ROCKVILLE, MD and SHENZHEN, CHINA, September 10, 2024—HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, a

ROCKVILLE, MD and SHENZHEN, CHINA, August 29, 2024—HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabol

ROCKVILLE, MD and SHENZHEN, CHINA, June 21, 2024—HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, annou